中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
1期
97-99
,共3页
瑞舒伐他汀%不稳定型心绞痛%高敏C反应蛋白%同型半胱氨酸%肌钙蛋白
瑞舒伐他汀%不穩定型心絞痛%高敏C反應蛋白%同型半胱氨痠%肌鈣蛋白
서서벌타정%불은정형심교통%고민C반응단백%동형반광안산%기개단백
rosuvastatin%unstable angina%high sensitive C-reactive protein%homocysteine%troponin
目的:观察瑞舒伐他汀治疗不稳定型心绞痛的疗效及其对血脂,高敏C反应蛋白(high sensitive C-reaction protein,hs-CRP),同型半胱氨酸(homocy steine,Hcy)和肌钙蛋白(troponin I,cTnI)的水平的影响。方法选择2010年1月~2012年12月就诊的不稳定心绞痛患者384例,随机分为观察组和对照组,每组各192例,对照组予以辛伐他汀治疗,观察组予以瑞舒伐他汀治疗。观察2组治疗后的疗效,及对血脂,hs-CRP,Hcy和cTnI水平的变化。结果观察组的总有效率为92.19%,明显优于对照组的81.25%,差异有统计学意义(χ2=9.044,P<0.01)。治疗前2组的血脂Hcy、hs-CRP和cTnI水平差异无统计学意义,治疗后2组血脂Hcy,hs-CRP和cTnI水平较治疗前显著降低(P<0.01),HDL-C水平较治疗前显著升高(P<0.01),而观察组的降低或者升高水平较对照组更为显著(P<0.01)。结论瑞舒伐他汀治疗不稳定型心绞痛不但能降低血脂还可以减轻其炎症反应,对于稳定动脉斑块,对于不稳定型心绞痛发生,发展和预防具有重要作用。
目的:觀察瑞舒伐他汀治療不穩定型心絞痛的療效及其對血脂,高敏C反應蛋白(high sensitive C-reaction protein,hs-CRP),同型半胱氨痠(homocy steine,Hcy)和肌鈣蛋白(troponin I,cTnI)的水平的影響。方法選擇2010年1月~2012年12月就診的不穩定心絞痛患者384例,隨機分為觀察組和對照組,每組各192例,對照組予以辛伐他汀治療,觀察組予以瑞舒伐他汀治療。觀察2組治療後的療效,及對血脂,hs-CRP,Hcy和cTnI水平的變化。結果觀察組的總有效率為92.19%,明顯優于對照組的81.25%,差異有統計學意義(χ2=9.044,P<0.01)。治療前2組的血脂Hcy、hs-CRP和cTnI水平差異無統計學意義,治療後2組血脂Hcy,hs-CRP和cTnI水平較治療前顯著降低(P<0.01),HDL-C水平較治療前顯著升高(P<0.01),而觀察組的降低或者升高水平較對照組更為顯著(P<0.01)。結論瑞舒伐他汀治療不穩定型心絞痛不但能降低血脂還可以減輕其炎癥反應,對于穩定動脈斑塊,對于不穩定型心絞痛髮生,髮展和預防具有重要作用。
목적:관찰서서벌타정치료불은정형심교통적료효급기대혈지,고민C반응단백(high sensitive C-reaction protein,hs-CRP),동형반광안산(homocy steine,Hcy)화기개단백(troponin I,cTnI)적수평적영향。방법선택2010년1월~2012년12월취진적불은정심교통환자384례,수궤분위관찰조화대조조,매조각192례,대조조여이신벌타정치료,관찰조여이서서벌타정치료。관찰2조치료후적료효,급대혈지,hs-CRP,Hcy화cTnI수평적변화。결과관찰조적총유효솔위92.19%,명현우우대조조적81.25%,차이유통계학의의(χ2=9.044,P<0.01)。치료전2조적혈지Hcy、hs-CRP화cTnI수평차이무통계학의의,치료후2조혈지Hcy,hs-CRP화cTnI수평교치료전현저강저(P<0.01),HDL-C수평교치료전현저승고(P<0.01),이관찰조적강저혹자승고수평교대조조경위현저(P<0.01)。결론서서벌타정치료불은정형심교통불단능강저혈지환가이감경기염증반응,대우은정동맥반괴,대우불은정형심교통발생,발전화예방구유중요작용。
Objective To observe the efifcacy of rosuvastatin in patients with unstable angina and its impact on the levels of lipids, high sensitive C-reactive protein (hs-CRP), homocysteine(Hcy) and troponin I (cTnI). Method 384 patients with unstable angina, from January 2010 to December 2012, were randomly divided into observation group and control group, each group had 192 cases, the control group received simvastatin, the observation group were gave rosuvastatin. The efficacy, and the levels of lipids, hs-CRP, Hcy and cTnI were observed after treatment. Results The total effective rate was 92.19%in observation group which was signiifcantly better than 81.25%in control group (χ2=9.044, P<0.01). Before treatment, the levels of TG , TC, LDL-C, HDL-C, Hcy, hs-CRP and cTnI showed no signiifcant difference, after treatment the levels of TG , TC and LDL-C, Hcy, hs-CRP and cTnI were signiifcantly lower than those before treatment (P<0.01), while, the levels of HDL-C signiifcantly increased than those before treatment (P<0.01), the reducing or increasing levels in observation group were more signiifcant compared with the control group (P<0.01). Conclusion Rosuvastatin treatment in unstable angina not only can reduce plasma lipid, but also reduce their inflammation, and stabilize the arterial plaque for unstable angina, it play an important role in development and prognosis.